Novo Nordisk A/S
NVO
$54.87
$0.571.05%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.03B | 4.10B | 4.03B | 4.02B | 2.89B |
| Total Depreciation and Amortization | 638.57M | 539.99M | 11.58M | 316.82M | 293.92M |
| Total Amortization of Deferred Charges | -- | -- | 36.44M | -- | -- |
| Total Other Non-Cash Items | 810.61M | 1.15B | -2.18B | 3.78B | 2.68B |
| Change in Net Operating Assets | 723.30M | -2.32B | -140.20M | -1.66B | 1.42B |
| Cash from Operations | 6.20B | 3.47B | 1.76B | 6.46B | 7.29B |
| Capital Expenditure | -2.23B | -1.89B | -2.30B | -1.79B | -1.51B |
| Sale of Property, Plant, and Equipment | -- | -- | -142.90K | 147.40K | -- |
| Cash Acquisitions | -- | -- | -11.65B | 0.00 | -96.39M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 62.82M | 952.03M | 911.93M | -1.29B | -1.38B |
| Cash from Investing | -2.17B | -941.31M | -13.04B | -3.08B | -2.99B |
| Total Debt Issued | 45.24B | 27.36B | 44.76B | 119.00M | 34.51B |
| Total Debt Repaid | -64.86B | -12.03B | -433.00M | -532.00M | -5.05B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 0.00 | -1.39B | -7.49B | -2.41B | -7.45B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -4.98B | 0.00 | -2.30B | 0.00 |
| Other Financing Activities | -26.78B | 26.78B | -- | -- | -5.33B |
| Cash from Financing | -7.03B | 768.93M | 5.26B | -2.71B | 2.41B |
| Foreign Exchange rate Adjustments | -123.21M | -12.13M | 102.47M | -51.28M | 6.06M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.12B | 3.28B | -5.91B | 618.46M | 6.71B |